Technical Analysis for SMMT - Summit Therapeutics plc

Grade Last Price % Change Price Change
grade C 1.405 -2.40% -0.03
SMMT closed down 2.4 percent on Friday, September 13, 2019, on 15 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical SMMT trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Pocket Pivot Bullish Swing Setup -2.40%
Stochastic Reached Overbought Strength -2.40%
Upper Bollinger Band Walk Strength -2.40%
Above Upper BB Strength -2.40%
Overbought Stochastic Strength -2.40%

Older signals for SMMT ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Summit Corporation plc, a drug discovery and development company, engages in the discovery and development of novel drug candidates to treat areas of high unmet medical need. The company licenses its drug discovery platform, known as Seglin technology, for the identification of new drug leads and candidates with the potential to target a range of diseases. Its pipeline consists of clinical stage programmes targeting Duchenne Muscular Dystrophy (DMD) and Clostridium difficile infection (CDI). The company provides SMT C1100, a small molecule Utrophin modulator for DMD patients that has completed Phase I clinical trial; and SMT 19969, a Phase I clinical trial completed novel molecule antibiotic for the treatment for initial CDI and prevention of recurrent disease. It is also engaged in other programmes that include OGA inhibitor programme for the treatment of dementia. The company has a technology license agreement with Bristol-Myers Squibb to access the Seglin technology platform. It has operations primarily in the United Kingdom and the United States. The company was formerly known as VASTox plc and changed its name to Summit Corporation Plc in July 2007. Summit Corporation plc was founded in 2003 and is headquartered in Abingdon, the United Kingdom.
Medicine Medical Specialties Diseases Drug Discovery Dementia Muscular Dystrophy Duchenne Muscular Dystrophy Clostridioides Difficile Clostridium Difficile Infection
Is SMMT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 2.46
52 Week Low 1.1
Average Volume 21,683
200-Day Moving Average 1.5217
50-Day Moving Average 1.3257
20-Day Moving Average 1.3193
10-Day Moving Average 1.369
Average True Range 0.0664
ADX 24.45
+DI 28.1957
-DI 11.0584
Chandelier Exit (Long, 3 ATRs ) 1.2508
Chandelier Exit (Short, 3 ATRs ) 1.3892
Upper Bollinger Band 1.4325
Lower Bollinger Band 1.2061
Percent B (%b) 0.88
BandWidth 17.160615
MACD Line 0.0224
MACD Signal Line 0.0076
MACD Histogram 0.0148
Fundamentals Value
Market Cap 17.4 Million
Num Shares 12.4 Million
EPS -0.36
Price-to-Earnings (P/E) Ratio -3.90
Price-to-Sales 4.01
Price-to-Book 26.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.47
Resistance 3 (R3) 1.47 1.46 1.46
Resistance 2 (R2) 1.46 1.44 1.45 1.45
Resistance 1 (R1) 1.43 1.43 1.44 1.43 1.45
Pivot Point 1.42 1.42 1.42 1.41 1.42
Support 1 (S1) 1.39 1.40 1.40 1.39 1.36
Support 2 (S2) 1.38 1.39 1.37 1.36
Support 3 (S3) 1.35 1.38 1.36
Support 4 (S4) 1.35